LumiThera
Oludayo Ogunsanwo MBA is a seasoned professional in clinical trial administration and document management with significant experience in the clinical research industry. Currently serving as Senior CTA at LumiThera, Inc. since May 2022, Oludayo has previously held positions including In-house CRA at ICON plc and Document Management Associate at PRA Health Sciences. Oludayo's career also includes roles at Boehringer Ingelheim and Phlexglobal, encompassing various responsibilities from document management to project support within clinical trials. Educational qualifications include a Master of Business Administration and a Bachelor's degree in Business Administration with a focus on Health Administration from Gwynedd Mercy University, as well as an Associate of Science in Science for Health Professions from Delaware County Community College.
This person is not in any offices
LumiThera
1 followers
At LumiThera, they are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. They will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area.